GOAL


Transition an unknown start-up company from private to public, creating awareness and documenting the opening bell at NASDAQ.

Tyme Technologies, Inc. is an emerging biotechnology company developing cancer therapeutics that are intended to be broadly effective across tumor types and have low toxicity profiles.

SOLUTION


325 positioned Tyme (NASDAQ: TYME) as a leader in developing cancer therapeutics by successfully building a sophisticated brand strategy and powerful online presence to become recognized as a well-established biotech company by the oncology community and the financial markets.

We leveraged social media to communicate to Tyme investors, clinicians, key opinion leaders and cancer organizations the benefits of SM-88. We bridged the conversation by developing Tyme’s business strategy and clearly articulated their actionable plan for delivering results and the potential for profit that investors sought. 325 participated in the uplisting of Tyme to the NASDAQ.

DELIVERABLES


BRAND STRATEGY
WEBSITE DESIGN + DEVELOPMENT
SOCIAL MEDIA
ABSTRACT POSTERS
INVESTOR PRESENTATION
IR/IPO WEBSITE TRANSITION
TRADESHOW DISPLAY 

Campaign Duration:
July 2017 – March 2018

STRATEGY


Develop the inherent value of the brand to generate interest, awareness, eliminate uncertainty and educate the market. From unknown to Instagram Biotech leader, 325 created the overall brand, assets and messaging collaborating with the Tyme team. From design and development of the Tyme website, brand strategy, corporate deck to trade show displays and poster abstracts for the Annual ASCO and ESMO Conferences, a strong, consistent, identifiable brand was launched.

We targeted and engaged audiences organically and built brand awareness and recognition immediately due to target-specific, audience-relevant content, natural in tone. Tyme ranked in the Top 9 and top post positions daily on Instagram with a targeted audience that included cancer foundations, patients, patient advocacy groups and financial institutions. Our posts reached thousands of new viewers on a weekly basis. We delivered compliancy and connected Instagram to the Tyme website to increase traffic.

Additionally, our strategy included educating clinicians, key opinion leaders and financial journalists on Twitter and LinkedIn by leveraging our proprietary methods and technologies to highlight the potential value and impact of Tyme’s technology SM-88. We leveraged similar tactics and strategies on Instagram and Facebook reaching a large population of patients, clinicians, and advocacy groups. Targeting each group with appropriate information regarding the medical efficacy and safety of SM-88.

CLIENT TESTIMONIAL


325 was instrumental in creating our multi-strategy digital and social marketing campaigns that successfully increased brand awareness and recognition and the public’s understanding of SM-88, the initial drug candidate for Tyme.

Michael Demurjian, Co-Founder, Tyme Technologies, Inc.

ABOUT TYME TECHNOLOGIES


Tyme Technologies, Inc. is an emerging biotechnology company developing cancer therapeutics that are intended to be broadly effective across tumor types and have low toxicity profiles.

ADDITIONAL CASE STUDIES


Click an image below to view more case studies.